These findings indicate that combining MEK inhibitors with KRAS(G12C) inhibitors in lung cancer, or potentially also BRAFV600E inhibitors in melanoma, may compromise the anti-tumour immune response and thus limit therapeutic impact and possible benefit with ICB combinations. This evidence concerns the gene KRAS and lung carcinoma.